Costs and outcomes of routine HIV oral pre-exposure prophylaxis implementation across different service delivery models and key populations in South Africa: a retrospective cohort study.

IF 12.8 1区 医学 Q1 IMMUNOLOGY
Cheryl Hendrickson, Kamban Hirasen, Constance Mongwenyana, Mariet Benade, Rutendo Bothma, Chantal Smith, Johan Meyer, Brooke E Nichols, Lawrence C Long
{"title":"Costs and outcomes of routine HIV oral pre-exposure prophylaxis implementation across different service delivery models and key populations in South Africa: a retrospective cohort study.","authors":"Cheryl Hendrickson, Kamban Hirasen, Constance Mongwenyana, Mariet Benade, Rutendo Bothma, Chantal Smith, Johan Meyer, Brooke E Nichols, Lawrence C Long","doi":"10.1016/S2352-3018(24)00295-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Despite several service delivery models that aim to improve uptake and persistence of pre-exposure prophylaxis (PrEP) in sub-Saharan Africa, the full costs of daily oral PrEP provision in routine care settings remain largely unknown. We aimed to evaluate outcomes and costs of daily oral PrEP delivery among key and priority populations at in-facility and community outreach programmes in South Africa.</p><p><strong>Methods: </strong>This retrospective cohort study was done at seven urban sites across South Africa with in-facility or community outreach PrEP service delivery models. We did top-down and bottom-up microcosting, from the provider perspective, of routine oral PrEP provision in programmes focusing on men who have sex with men (MSM), female sex workers, and adolescent girls and young women (aged 15-24 years) who initiated oral PrEP between March 12, 2018, and Aug 13, 2019. The primary outcome was PrEP in-hand at 6 months, defined as having sufficient PrEP drug dispensed at the last visit to have the drug available 6 months after PrEP initiation. A subset of enrolled participants with sufficient potential follow-up were included in a 12-month outcome analysis. We report the cost per client initiated on PrEP in 2021 US dollars.</p><p><strong>Findings: </strong>We enrolled 1281 people aged at least 15 years who initiated oral PrEP in either in-facility or community outreach programmes between March 12, 2018, and Aug 13, 2019. The proportion of participants with PrEP in-hand at 6 months varied from 41·8% (95% CI 31·9-52·2; 41 of 98 participants) at one MSM-focused clinic to 0% (0-6·7; 0 of 53 participants) in an MSM-focused outreach programme. Among 633 clients receiving oral PrEP with the potential for 12 months follow-up, 86 (13·6%) had PrEP in-hand at 12 months. The mean average 6-month costs per client initiating oral PrEP ranged from US$29 (95% CI 26-31) to $590 (488-692), with higher costs generally observed for in-facility programmes ($152, 140-164) than for outreach programmes ($84, 79-88). The mean average monthly cost per client with PrEP in-hand at 6 months ranged from $18 (15-21) to $160 (126-194).</p><p><strong>Interpretation: </strong>Costs and outcomes of daily oral PrEP provision across several populations and service delivery models in real-world settings show substantial variability. Policy makers should consider this variability when planning further scale-up of oral PrEP programmes in South Africa and the sub-Saharan Africa region to maximise opportunities to improve efficiency based on local context.</p><p><strong>Funding: </strong>The US President's Emergency Plan for AIDS Relief, the US Agency for International Development, and the National Institutes of Health.</p>","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":"12 2","pages":"e130-e142"},"PeriodicalIF":12.8000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Hiv","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/S2352-3018(24)00295-9","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Despite several service delivery models that aim to improve uptake and persistence of pre-exposure prophylaxis (PrEP) in sub-Saharan Africa, the full costs of daily oral PrEP provision in routine care settings remain largely unknown. We aimed to evaluate outcomes and costs of daily oral PrEP delivery among key and priority populations at in-facility and community outreach programmes in South Africa.

Methods: This retrospective cohort study was done at seven urban sites across South Africa with in-facility or community outreach PrEP service delivery models. We did top-down and bottom-up microcosting, from the provider perspective, of routine oral PrEP provision in programmes focusing on men who have sex with men (MSM), female sex workers, and adolescent girls and young women (aged 15-24 years) who initiated oral PrEP between March 12, 2018, and Aug 13, 2019. The primary outcome was PrEP in-hand at 6 months, defined as having sufficient PrEP drug dispensed at the last visit to have the drug available 6 months after PrEP initiation. A subset of enrolled participants with sufficient potential follow-up were included in a 12-month outcome analysis. We report the cost per client initiated on PrEP in 2021 US dollars.

Findings: We enrolled 1281 people aged at least 15 years who initiated oral PrEP in either in-facility or community outreach programmes between March 12, 2018, and Aug 13, 2019. The proportion of participants with PrEP in-hand at 6 months varied from 41·8% (95% CI 31·9-52·2; 41 of 98 participants) at one MSM-focused clinic to 0% (0-6·7; 0 of 53 participants) in an MSM-focused outreach programme. Among 633 clients receiving oral PrEP with the potential for 12 months follow-up, 86 (13·6%) had PrEP in-hand at 12 months. The mean average 6-month costs per client initiating oral PrEP ranged from US$29 (95% CI 26-31) to $590 (488-692), with higher costs generally observed for in-facility programmes ($152, 140-164) than for outreach programmes ($84, 79-88). The mean average monthly cost per client with PrEP in-hand at 6 months ranged from $18 (15-21) to $160 (126-194).

Interpretation: Costs and outcomes of daily oral PrEP provision across several populations and service delivery models in real-world settings show substantial variability. Policy makers should consider this variability when planning further scale-up of oral PrEP programmes in South Africa and the sub-Saharan Africa region to maximise opportunities to improve efficiency based on local context.

Funding: The US President's Emergency Plan for AIDS Relief, the US Agency for International Development, and the National Institutes of Health.

在南非不同服务提供模式和关键人群中实施常规艾滋病毒口服暴露前预防的成本和结果:一项回顾性队列研究
背景:尽管有几种服务提供模式旨在提高撒哈拉以南非洲地区暴露前预防(PrEP)的接受程度和持久性,但在常规护理机构中每日口服PrEP提供的全部成本在很大程度上仍然未知。我们的目的是评估南非设施内和社区外展项目中重点和优先人群每日口服PrEP的结果和成本。方法:这项回顾性队列研究在南非的七个城市站点进行,采用设施内或社区外展PrEP服务交付模式。我们从提供者的角度,对2018年3月12日至2019年8月13日期间开始口服PrEP的男男性行为者(MSM)、女性性工作者以及青春期女孩和年轻女性(15-24岁)的常规口服PrEP提供进行了自上而下和自下而上的微观成本计算。主要终点是6个月时PrEP在手,定义为在PrEP开始6个月后,在最后一次就诊时配发了足够的PrEP药物。在12个月的结果分析中纳入了一组有足够随访潜力的入组参与者。我们以2021年美元为单位报告每个启动PrEP的客户的成本。研究结果:我们招募了1281名年龄在15岁以上的人,他们在2018年3月12日至2019年8月13日期间在设施内或社区外展项目中开始口服PrEP。6个月时PrEP在手的参与者比例从41.8%不等(95% CI为31.9 - 52.2;在一家以男男性行为为中心的诊所(98名参与者中有41名)为0%(0-6·7;(53名参与者中的0人)参加了以男男性行为者为重点的外展计划。在633名接受口服PrEP并有可能随访12个月的患者中,86名(13.6%)在12个月时使用了PrEP。每位客户启动口服PrEP的平均6个月费用从29美元(95% CI 26-31)到590美元(488-692)不等,通常观察到设施内方案的费用(152,140 -164美元)高于外展方案(84,79 -88美元)。在6个月的时间里,每位获得PrEP的患者每月平均费用从18美元(15-21美元)到160美元(126-194美元)不等。解释:在现实环境中,在不同人群和服务提供模式中,每日口服PrEP的成本和结果存在很大差异。决策者在规划南非和撒哈拉以南非洲地区进一步扩大口服PrEP规划时应考虑到这种可变性,以便根据当地情况最大限度地提高效率。资助:美国总统艾滋病紧急救援计划、美国国际开发署和美国国立卫生研究院。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Lancet Hiv
Lancet Hiv IMMUNOLOGYINFECTIOUS DISEASES&-INFECTIOUS DISEASES
CiteScore
19.90
自引率
4.30%
发文量
368
期刊介绍: The Lancet HIV is an internationally trusted source of clinical, public health, and global health knowledge with an Impact Factor of 16.1. It is dedicated to publishing original research, evidence-based reviews, and insightful features that advocate for change in or illuminates HIV clinical practice. The journal aims to provide a holistic view of the pandemic, covering clinical, epidemiological, and operational disciplines. It publishes content on innovative treatments and the biological research behind them, novel methods of service delivery, and new approaches to confronting HIV/AIDS worldwide. The Lancet HIV publishes various types of content including articles, reviews, comments, correspondences, and viewpoints. It also publishes series that aim to shape and drive positive change in clinical practice and health policy in areas of need in HIV. The journal is indexed by several abstracting and indexing services, including Crossref, Embase, Essential Science Indicators, MEDLINE, PubMed, SCIE and Scopus.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信